The bioavailability and therapeutic properties of BL-S 640 in rodents were compared with those of cephalothin, cephaloridine, and cefazolin after parenteral administration, and cephalexin after oral administration. When given intramuscularly in dosages of 5 to 40 mg/kg, peak concentrations of BL-S 640 in the blood of mice were proportional to dose, but when given orally, they were proportional only up to a dose of 25 mg/kg. After either route of administration, the concentration of BL-S 640 in the blood declined at a slower rate than that of the control compounds. Rats The bioavailability and therapeutic properties of BL-S 640 were assessed by determining its concentration in blood, the percentage of recovery in urine, and the efficacy of the drug in the treatment of experimental infections after parenteral or oral administration to rodents. In studies using the parenteral route of administration, BL-S 640 was compared with cephalothin, cephaloridine, and cefazolin; in those involving the oral route, cephalexin was the control compound.
The bioavailability and therapeutic properties of BL-S 640 were assessed by determining its concentration in blood, the percentage of recovery in urine, and the efficacy of the drug in the treatment of experimental infections after parenteral or oral administration to rodents. In studies using the parenteral route of administration, BL-S 640 was compared with cephalothin, cephaloridine, and cefazolin; in those involving the oral route, cephalexin was the control compound.
MATERIALS AND METHODS
Cephalosporins and bacteria. The antimicrobial agents and microorganisms used in this study have been described previously (1).
Antibiotic concentration in blood. Male SwissWebster mice, weighing 20 (±1) g, were given 0.2 ml of antibiotic solutions at appropriate concentrations either by intramuscular injection or by gavage. The vehicle for the parenteral route was 0.01% phosphate buffer at pH 7.0, and for the oral route Tween-CMC (a preparation containing 0.93% Tween 40 and 0.4% carboxymethylcellulose HV Type 70). Eight animals were used for each dose level. Those receiving the compound per os were fasted for 4 h prior to drug administration. Blood samples (0.03 ml) were obtained from the orbital sinuses by means of heparinized capillary tubes (Clay Adams) at 0.25, 0.5, 1, and 1.5 h after intramuscular (i.m.) and 0.5, 1, 2, and 3.5 h after oral administration of the compound. Paper disks, 6.35 mm in diameter, were impregnated with the blood, and the antibiotic activity was assayed by the diffusion technique using seed agar (BBL) inoculated with Bacillus subtilis ATCC 6633 or Sarcina lutea ATCC 9497. A standard line relating the diameter of the inhibition zone to drug concentration was obtained by assaying the compounds at known concentrations in heparinized mouse blood.
Recovery in urine. Male Sprague-Dawley rats, weighing 200 (±10) g, received a dose of 50 mg of cephalosporin per kg in 5 ml of Tween-CMC by gavage. Four rats were used per compound. The animals were fasted for 18 h before dosing. Although water was available ad libitum, the animals were hydrated with 5 ml of water at 3 and 6 h after dosing. The rats were housed individually in metabolism cages, and urine specimens were collected over dry ice during intervals of 0 to 6 and 6 to 24 h after drug administration. Portions (0.03 ml) of appropriate dilutions of urine were placed on paper disks (6.35 mm in diameter), and the antibiotic activity was assayed by the diffusion technique on seed agar inoculated with B. subtilis ATCC 6633. A standard line relating the diameter of the inhibition zone to drug concentration was obtained by assaying the compounds at known concentrations in urine collected from untreated control animals.
Treatment of systemically infected mice. Male Swiss-Webster mice, weighing 20 (41) g, were challenged intraperitoneally with 0.5 ml of a bacterial suspension containing sufficient organisms to kill untreated animals within 72 h. The suspending medium for Streptococcus pneumoniae, Streptococcus pyogenes, and Klebsiella pneumoniae was brain heart infusion broth (Difco). Staphylococcus aureus no. 2 was suspended in broth containing 2% mucin; the remaining organisms were suspended in medium containing 4% hog gastric mucin (type 1701w, Wilson Laboratories, Inc, Park Forest South, Ill.). The ani-mals received 0.2 ml of appropriate concentrations of antibiotic either by i.m. injection or by gavage. Five mice were used for each dose level. The animals were treated twice in accordance with a schedule given in the tables. The number of mice surviving the challenge for 3 or 5 days (depending on the test organism) was recorded and the PD50-the dose in mg/kg required to protect half the infected animals from death-was then estimated by means of a log probit plot.
Treatment of intracystically infected rats. The bladder of female Long-Evans rats, weighing approximately 225 g, was surgically exposed under anesthesia. Urine was drained, and a challenge of 1.8 x 107 cells of Proteus mirabilis strain no. 1 was injected into the bladder. After positioning the bladder in place the incision was closed with wound clips. Treatment with BL-S 640 or cephalexin was initiated 24 h after infection. The following doses were given orally, four times a day for 3 days, to groups of eight animals per dose level: 0.04, 0.2, 1, 5, and 25 mg/kg. Ten animals were challenged but left untreated, and five animals were sham operated. The rats were autopsied four days after being infected, and the number of viable organisms in the bladder and the kidneys was determined.
RESULTS
Bioavailability studies. (i) Concentration in murine blood. When given i.m., peak antibiotic concentrations of BL-S 640 and the three control compounds were observed 0.25 h after drug administration. This is illustrated in Fig.  1 (left panel) for a dose of 20 mg/kg. At this dose, cefazolin reached a peak concentration of 34 gg/ml, BL-S 640 of 32 ,ug/ml, cephaloridine of 23 gg/ml, and cephalothin of 17 ,g/ml. The concentration of BL-S 640 in the blood declined at a slower rate than that of the control cephalosporins. With all compounds peak concentrations were proportional to dose in the range tested (Fig. 1, right Areas (fCdt) under the blood level curves (C), for 0 < t < 1.5 h, were determined and related to cephalothin, chosen as the reference compound.
Relative areas (JCdt/fCre,dt) for cephaloridine, cefazolin, and BL-S 640 increased between the doses of 5 and 10 mg/kg and remained virtually constant for doses of 10, 20, and 40 mg/kg (Table 1) . At these higher doses, the relative area was 2 for cephaloridine, 3 for cefazolin, and 4 for BL-S 640.
When given orally, BL-S 640 and cephalexin reached peak concentrations 0.5 h after administration, as illustrated in Fig. 2 (left panel) , for a dose of 25 mg/kg. At this dose, the peak concentration of BL-S 640 was 22 Ag/ml, and that of cephalexin was 15 Ag/ml. The concentration of BL-S 640 declined at a somewhat slower rate than that of cephalexin. For both compounds peak concentrations were proportional with dose only up to a dose of 25 mg/kg (Fig. 2, right   panel) . VOL. 7, 1975 Areas under the blood level curves, for 0 < t < 3.5 h, were determined. At a dose of 3.1 mg/kg, this area was 3.5 times larger for BL-S 640 than for cephalexin (Table 1) . With increasing dose this ratio progressively declined, and at a dose of 100 mg/kg it was 1.8.
(ii) Recovery in rat urine. Rats receiving 50 mg of BL-S 640 per kg orally excreted an average of 39% of the administered dose in urine. Under identical conditions 57% of cephalexin was recovered in urine. A small fraction of the recovered activity of BL-S 640 was due to a metabolite detectable by paper chromatography. Cephalexin gave no detectable antibiotically active metabolite.
Efficacy determinations. (i) Treatment of systemically infected mice. When given i.m., BL-S 640 was remarkably effective, with a PD,o per treatment of 1 mg/kg or less against infections with Escherichia coli, P. mirabilis, P. vularis, and one of two strains of K. pneumoniae (Table 2 ). Significantly higher doses of the other cephalosporins were required to achieve comparable protection. In the treatment of animals infected with Proteus morganii and Providencia stuartii, BL-S 640 was also more active than the control compounds, and against infections with Enterobacter cloacae BL-S 640 alone was effective. Finally, BL-S 640 was generally as active as the most active of the control compounds in the treatment of mice challenged with Proteus rettgeri, Providencia alcalifaciens, K. pneumoniae strain no. 7 (Table 2) , S. aureus, S. pneumoniae, and S. pyogenes (Table 3) .
Per os, BL-S 640 was therapeutically superior to cephalexin in experimental infections with gram-negative organisms. Once again, BL-S 640 was remarkably active, with PD,0 per treatment of 1 to 2 mglkg against infections with E. coli, P. mirabilis, P. vulgaris, and strain no. 1 of K. pneumoniae (Table 4 ). Against infections with other gram-negative organisms, the PD,0 per treatment of BL-S 640 ranged from 6 to 50 mg/kg, which is 8 to more than 25 times lower than that of cephalexin. In the treatment of mice with staphylococcal infections, the two cephalosporins were about equally effective, but against streptococcal infections BL-S 640 was 20 to 90 times more active than cephalexin (Table 5) .
(ii) Oral treatment of intracystically infected rats. The therapeutic efficacy of BL-S 640 and cephalexin given orally to rats suffering from a urinary tract infection was judged by the ability of the compounds to significantly a Animals infected with penicillinase-producing staphylococcal strains (no. 2 and 3) were treated 0 and 2 h after infection, the others were treated 1 and 3.5 h after infection. reduce the number of infecting organisms in the bladder and the kidneys in comparison with animals left untreated. Four days after infection with a strain of P. mirabilis, these organs contained about 25 to 30 million viable organisms in untreated rats, which is virtually identical with the challenge (Table 6 ). BL-S 640 reduced the number of infecting organisms to less that 1,000 in the bladder when 1 mg/kg, and in the kidneys when 0.2 mg/kg, were administered four times a day for 3 days. A dose of 5 mg/kg was required to achieve comparable results by the same regimen with cephalexin.
DISCUSSION
Compared to the other cephalosporins, the therapeutic efficacy of BL-S 640 was frequently in excess of what would have been predicted on the basis of of its comparative activity in vitro (1). A few examples will illustrate this point. BL-S 640 was about 10 times more effective than cefazolin against infections with two strains of E. coli (Table 2) but only half as active as cefazolin against the same strains in vitro. Similarly, BL-S 640 and cephaloridine were about equally effective in the treatment of animals infected with strains 1 and 2 of S. aureus (Table 3) , although in vitro cephaloridine was 64 times more active than BL-S 640.
Compared with cephalexin against two strains of S. pneumoniae, BL-S 640 was 50 to 90 times more effective in vivo (Table 5 ) but only 16 times more active in vitro. It is not unreasonable to assume that the considerably longer half-life of BL-S 640 in blood contributed to its therapeutic superiority.
In view of its antibiotic and therapeutic properties, we believe that BL-S 640 deserves further consideration as an antibiotic agent for clinical use.
